July 2026 Research Update

This month, studies in children and families reinforced that hereditary spastic paraplegia (HSP) is not one single condition, but a group of many genetic conditions that can look similar at first. Across cohorts from different countries, most pediatric cases were inherited in a recessive way, and many children had additional features beyond leg spasticity, such as learning challenges, seizures, or balance problems. This matters because the same walking pattern can have different genetic causes, and those causes can come with different associated symptoms and different expectations over time. [1] [2]

In a 21-child series from Northern India, many different genes were found, with SPG35 the most frequent subtype in that group and several newly described variants. The children had a typical gap between when symptoms began and when a genetic diagnosis was made, showing how long it can take to identify the cause even when HSP is suspected. The main message is that genetic diversity is the rule in pediatric HSP, even within one center. [2]

In a 21-child group from the Eastern Levant, most cases were recessive and many were from consanguineous families, with variants spread across many known HSP genes. The clinical picture ranged from more "pure" spastic paraplegia to complex presentations with intellectual disability, ataxia, or seizures, and brain MRI findings varied from normal-appearing to changes like corpus callosum thinning or nonspecific white matter differences. Taken together, these results underline why broad genetic testing is often needed in regions where recessive conditions are more common. [1]

A separate family report showed how similar early motor symptoms can come from different genetic diagnoses even among siblings in the same household. In three affected siblings, different combinations of genetic findings were reported alongside distinct MRI patterns and different rehabilitation courses, which illustrates that appearance alone may not identify the underlying condition. This helps explain why families sometimes receive unexpected results from genetic testing, including more than one contributing genetic factor. [3]

For patients and caregivers, this month mainly adds clarity about why the diagnostic journey can be complicated in childhood-onset HSP: many genes can lead to overlapping walking and stiffness symptoms. These studies suggest that in pediatric HSP, additional symptoms (like learning differences, balance problems, or seizures) and MRI findings can be part of the picture, but they vary widely by genetic cause and by family. This does not point to a single new treatment, but it supports the idea that a specific genetic diagnosis is often needed to understand what else to watch for and to make research studies more comparable. Important uncertainties remain, including how well results from one region apply to another and how often more than one genetic change contributes in a single person. [1] [2] [3]

This month brought a clearer, more structured picture of KIF1A-associated neurological disease, a genetic condition that can include spastic paraplegia. In a 51-person cross-sectional study using standardized rating scales, spasticity tended to progress with age and leg weakness was common, alongside a wide range of movement disorders such as stereotyped movements, ataxia, tremor, or dystonia. This matters because it describes what families may recognize day-to-day: changes in walking, stiffness, balance, and extra movements can all be part of the same genetic condition. [4]

The same study also highlighted that walking outcomes can change over time: many individuals achieved independent walking in early childhood, but fewer kept independent ambulation at their most recent follow-up. One specific genetic change (p.Glu253Lys) was linked to a more severe presentation in this group, showing that not all KIF1A variants behave the same way. These details help set expectations for research and may help families interpret why two people with the same overall diagnosis can have different levels of mobility. [4]

For patients and caregivers affected by KIF1A-related disease, this is the kind of evidence that may matter now for understanding the range of possible symptoms and how they can shift with age, even though it does not test a treatment. It helps clarify that spasticity and weakness are often central, and that additional movement problems are common enough to be considered part of the condition rather than "separate" issues. It also underscores that some people may lose walking ability over time, but the study does not explain why this happens in each person or predict an individual course. The findings are most useful for describing the condition consistently in clinics and for designing future studies that measure change in meaningful ways. [4]

This month included case reports that expand what specific rare genetic forms of spastic paraplegia can look like, but they also come with the limits of single-person evidence. Together, these reports show that both childhood-onset and adult-onset spastic paraplegia can have distinctive additional features, and that genetic testing can sometimes reveal a diagnosis that is uncommon in a given country or age group. This matters mainly for diagnosis and for building a more complete catalog of how different genes can present. [5] [6]

One report described a child with Troyer syndrome (SPG20) due to a newly identified splice-site variant, with developmental delay, spastic gait, and speech difficulties. The authors added laboratory work showing abnormal RNA splicing and a shortened spartin protein that did not localize normally to lipid droplets, alongside increased lipid droplet accumulation in cells. This provides a plausible biological explanation for why that specific genetic change could cause disease, but it is still based on one patient. [5]

Another report described a 51-year-old woman with a likely pathogenic MFN2 variant and a rapidly progressive spastic paraplegia picture with extensive bilateral white matter abnormalities on brain MRI. The work-up for other causes was reported as unrevealing, and the authors proposed MFN2 as the likely explanation, broadening the known MFN2-related spectrum to include prominent central nervous system involvement. Because this is a single case without family segregation, it is best seen as an alert to a possible diagnosis rather than a firm rule about what MFN2 always causes. [6]

For families, these reports may matter most when someone has an unusual combination of symptoms or an atypical age of onset and is searching for a genetic explanation. They help clarify that specific genes like SPG20 or MFN2 can present with features beyond leg spasticity, such as developmental differences in childhood or striking MRI changes in adulthood. At the same time, single-case evidence cannot tell how common these presentations are or predict outcomes for others with the same variant. The main value right now is improving recognition and interpretation of rare genetic findings, which can support future research and more accurate diagnosis. [5] [6]

This month, several preclinical studies suggested that different HSP genes can disrupt cells in very different ways, even if the outward symptom is similar leg spasticity. Rather than pointing to one shared pathway, these studies paint a picture of multiple "routes" to nerve dysfunction, including problems with zinc balance, cell membranes and fats, energy use, and gene regulation. This matters for the long term because future treatments may need to match the specific genetic mechanism rather than treating all HSP as biologically identical. [7] [8] [9] [10]

One study used human stem cell-derived brain models to examine an Alu-mediated SPAST exon 17 deletion that created a fusion transcript and reduced ZnT6 (a zinc transporter). In that model, reduced ZnT6 was linked to zinc buildup in cells and fragmentation of the Golgi (a cell structure involved in processing and shipping proteins), along with increased amyloid-beta and ubiquitin aggregation. The authors reported that zinc chelation or blocking a Golgi protein (GRASP55) restored Golgi integrity and reduced amyloid-beta in the model, which is an early signal of a potentially "druggable" vulnerability in this specific mechanism. [7]

In fruit fly models of ATL1-related HSP, mutations tied to more complex disease caused worse movement, development, and survival than mutations tied to a more pure spastic paraplegia picture. The pure-mutation models showed lipid droplet buildup in nerves that partially improved with an LXR agonist, while the complex-mutation models instead showed disruption of the neuronal endoplasmic reticulum and did not show the same lipid droplet changes. This adds a concrete example of why different variants in the same gene can lead to different symptoms: they may disrupt different parts of the cell. [8]

For SPG56 (CYP2U1), zebrafish knockouts and patient-derived neurons pointed toward problems in early brain network development and cell energy use. The zebrafish had increased mortality and movement problems, along with changes in genes linked to cell cycle, nerve development, and energy production, plus abnormal patterns of brain activity measurements. This supports the idea that in at least some forms of HSP, important changes may start during development rather than only being a slow wear-and-tear process in adulthood. [9]

A genetic mechanism study in a large family with X-linked complex spastic paraplegia reported that a 149-kb DNA insertion near SOX3 altered 3D genome organization and disrupted SOX3 regulation in patient-derived neurons. The results support a "position effect," meaning the gene itself may be intact but its control switches are rewired, changing when and how strongly it turns on. This adds to the ways genetic changes can cause HSP, including structural DNA changes that affect gene regulation rather than changing the gene coding sequence. [10]

A separate clinical cohort in Brazil described SPG46 due to biallelic GBA2 mutations, with early-onset progressive spastic paraplegia plus cerebellar ataxia, dysarthria, and cognitive impairment in all reported individuals. The authors noted cerebellar atrophy in some and a recurrent variant suggesting a founder effect, showing how specific forms of complex HSP can cluster in certain populations. While this is a human study, it fits with the broader message from this month that distinct genetic causes often come with a recognizable bundle of additional symptoms. [11]

For patients and caregivers, this body of work is mainly early research, but it helps clarify why "one-size-fits-all" explanations for HSP often fall short. These studies suggest specific biological weak points for certain genetic forms, such as zinc handling and Golgi health in a SPAST fusion model, or lipid versus ER problems depending on the ATL1 mutation type. The SOX3 and CYP2U1 studies also widen what counts as a disease-causing change, from altered gene regulation to possible neurodevelopment and energy-related disruptions. What remains uncertain is whether lab fixes like zinc chelation, GRASP55 blockade, or LXR agonists translate into benefits for people, since these results were not tested in clinical trials. [7] [8] [9] [10] [11]